carbidopa-levodopa
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03761004 | Jan → Sep 2019 | — | Hong Kong WD Pharmaceutical Co., Limited | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06587217 | Oct 2024 → Apr 2025 | parkinsonian disorder | University of Michigan | Completed | No outcome recorded |
| Phase 1/2 | NCT06219915 | Mar → May 2024 | parkinsonian disorder | University of Michigan | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05087914 | Nov 2021 → Dec 2023 | — | Northwestern University | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05463367 | Jan 2021 → Jun 2025 overdue | chronic pain syndrome, opiate dependence, substance abuse | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03451500 | Jul 2018 → Oct 2019 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03023059 | May 2017 → Mar 2020 | age-related macular degeneration | Snyder, Robert W., M.D., Ph.D., P.C. | Completed | No outcome recorded |
| Phase 2 | NCT00869791 | Nov 2008 → Jun 2009 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 32 trials · 2 met primary | ||||||
| Phase 3 | NCT03670953 | Nov 2018 → Jun 2021 | Parkinson disease | Impax Laboratories, LLC | Completed | Met primary |
| Phase 3 | NCT00974974 | Sep 2009 → Jan 2011 | Parkinson disease | Impax Laboratories, LLC | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT00590122 | Oct 2006 → Oct 2008 | Parkinson disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT01528592 | Jun 2011 → Jul 2012 | Parkinson disease | Northwestern University | Completed | No outcome recorded |
| — | NCT00715520 | Apr 2007 → Sep 2016 | ischemic stroke | Emory University | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT05285683 Comparator | Jan 2024 → Dec 2027 expected | chronic pain syndrome | University of Rochester | Recruiting | No outcome recorded |
| Phase 2 | NCT05962957 Comparator | Aug 2023 → Sep 2024 | Parkinson disease | Mostafa Bahaa | Completed | No outcome recorded |
| Phase 2 | NCT03576638 Comparator | Jul 2018 → Jan 2019 | Parkinson disease | Intec Pharma Ltd. | Unknown | No outcome recorded |
Press releases naming this drug 30 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | carbidopa/levodopa | “An Open Label Phase 2 Study to Assess the Pharmacokinetics of the Accordion Pill Carbidopa-Levodopa Compared to Immediate Release Carbidopa-Levodopa in Patients With Parkinson's Disease” NCT03576638 ↗16“OBJECTIVE: To assess the efficacy and safety of IPX203 vs immediate-release carbidopa-levodopa in patients with Parkinson disease who are experiencing motor fluctuations.” PMID 37578800 ↗ Oct 2023 “oral administration of pro-dopaminergic medications carbidopa/levodopa (CD/LD) and methylphenidate will modulate the brain signature of chronic pain” NCT05285683 ↗ “BACKGROUND: IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD).” PMID 30425824 ↗ Oct 2018 “experimental drug product: extended-release carbidopa-levodopa capsules” NCT00869791 ↗ “Carbidopa-levodopa (Sinemet)at subjects current stable dose” NCT00590122 ↗ |
| Known as | CD/LD | “oral administration of pro-dopaminergic medications carbidopa/levodopa (CD/LD) and methylphenidate will modulate the brain signature of chronic pain” NCT05285683 ↗1“BACKGROUND: IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD).” PMID 30425824 ↗ Oct 2018 |
| Known as | IPX066 | “BACKGROUND: IPX066 is an extended-release (ER) oral formulation of carbidopa-levodopa (CD-LD).” PMID 30425824 ↗ Oct 2018 |
| Known as | IR CD-LD | “Two-phase 3 studies of ER CD-LD vs. immediate-release (IR) CD-LD (ADVANCE-PD) and vs. CD-LD + entacapone (CLE; ASCEND-PD) in subjects with advanced PD included a 6-week,...” PMID 30425824 ↗ Oct 2018 |
| Known as | Sinemet | “Carbidopa-levodopa (Sinemet)at subjects current stable dose” NCT00590122 ↗1“Immediate release CD/LD (Sinemet)” NCT03576638 ↗ |
| Route | Oral | “conventional immediate release oral levodopa” NCT00590122 ↗ |